Arsenic Trioxide and Ascorbic Acid May Represent a Promising Treatment Strategy for Acute Myelogenous Leukemia

Apr 19, 2001, 01:00 ET from Cell Therapeutics, Inc.

    SEATTLE, April 19 /PRNewswire/ -- A report published in the British
 Journal of Haematology demonstrated enhanced killing effects against leukemia
 cells isolated from patients with acute myelogenous leukemia (AML) when
 treated with a combination of arsenic trioxide and ascorbic acid. The authors
 concluded that additional studies on the combination of arsenic trioxide and
 ascorbic acid are warranted.
     TRISENOX(TM), marketed by Cell Therapeutics, Inc. (Nasdaq:   CTIC) (cti), is
 a pharmaceutical grade of arsenic trioxide, which has been approved by the FDA
 to treat patients with relapsed or refractory acute promyelocytic leukemia
 (APL). TRISENOX is currently being studied in over 20 clinical trials in a
 variety of blood cancers and solid tumors, including a study that combines
 TRISENOX with ascorbic acid.
     "This is very exciting news, which suggests that the mechanism may be
 extended to other types of cancer," stated James A. Bianco, M.D., President
 and CEO of cti.
     Researchers from the University of Vienna, Austria, suggest that the
 combination of arsenic trioxide and ascorbic acid may be particularly useful
 for treating AML patients who are naturally resistant to arsenic trioxide and
 for overcoming acquired resistance to arsenic trioxide in patients with APL.
 
     About AML
     According to the American Cancer Society, acute myelogenous leukemia is
 the most common adult leukemia with about 10,000 new cases expected in 2001.
 The average age of a patient with AML is 65 years.
     cti is committed to developing an integrated portfolio of oncology
 products aimed at making cancer more treatable.
     This announcement includes forward-looking statements that involve a
 number of risks and uncertainties, the outcome of which could materially
 and/or adversely affect actual future results. Specifically, the risks and
 uncertainties that could affect the development of cti's products under
 development include risks associated with preclinical and clinical
 developments in the biopharmaceutical industry in general and of cti's
 products under development in particular including, without limitation, the
 potential failure of all compounds to prove safe and effective for treatment
 of disease, determinations by regulatory, patent and administrative
 governmental authorities, competitive factors, technological developments,
 costs of developing, producing and selling cti's products under development,
 and the risk factors listed or described from time to time in the Company's
 filings with the Securities and Exchange Commission including, without
 limitation, the Company's most recent registrations on Forms 10-K, 8-K, S-3
 and 10-Q.
 
 

SOURCE Cell Therapeutics, Inc.
    SEATTLE, April 19 /PRNewswire/ -- A report published in the British
 Journal of Haematology demonstrated enhanced killing effects against leukemia
 cells isolated from patients with acute myelogenous leukemia (AML) when
 treated with a combination of arsenic trioxide and ascorbic acid. The authors
 concluded that additional studies on the combination of arsenic trioxide and
 ascorbic acid are warranted.
     TRISENOX(TM), marketed by Cell Therapeutics, Inc. (Nasdaq:   CTIC) (cti), is
 a pharmaceutical grade of arsenic trioxide, which has been approved by the FDA
 to treat patients with relapsed or refractory acute promyelocytic leukemia
 (APL). TRISENOX is currently being studied in over 20 clinical trials in a
 variety of blood cancers and solid tumors, including a study that combines
 TRISENOX with ascorbic acid.
     "This is very exciting news, which suggests that the mechanism may be
 extended to other types of cancer," stated James A. Bianco, M.D., President
 and CEO of cti.
     Researchers from the University of Vienna, Austria, suggest that the
 combination of arsenic trioxide and ascorbic acid may be particularly useful
 for treating AML patients who are naturally resistant to arsenic trioxide and
 for overcoming acquired resistance to arsenic trioxide in patients with APL.
 
     About AML
     According to the American Cancer Society, acute myelogenous leukemia is
 the most common adult leukemia with about 10,000 new cases expected in 2001.
 The average age of a patient with AML is 65 years.
     cti is committed to developing an integrated portfolio of oncology
 products aimed at making cancer more treatable.
     This announcement includes forward-looking statements that involve a
 number of risks and uncertainties, the outcome of which could materially
 and/or adversely affect actual future results. Specifically, the risks and
 uncertainties that could affect the development of cti's products under
 development include risks associated with preclinical and clinical
 developments in the biopharmaceutical industry in general and of cti's
 products under development in particular including, without limitation, the
 potential failure of all compounds to prove safe and effective for treatment
 of disease, determinations by regulatory, patent and administrative
 governmental authorities, competitive factors, technological developments,
 costs of developing, producing and selling cti's products under development,
 and the risk factors listed or described from time to time in the Company's
 filings with the Securities and Exchange Commission including, without
 limitation, the Company's most recent registrations on Forms 10-K, 8-K, S-3
 and 10-Q.
 
 SOURCE  Cell Therapeutics, Inc.